CMPS Company Profile and Key Details

CMPS has shown sold momentum, gaining 4.43% over the past week and 12.12% over the past quarter, though year-to-date performance is up 5.94%. Short-term trend indicators are bearishly aligned (SMA20 5.69%, SMA50 5.79%, SMA200 35.28%). The stock’s 14-day RSI is 52.64 (neutral), while the ATR of 0.65 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.64% below its high and over 225.78% above its low. Average 10-day trading volume of 3.28 million shares is below the 3-month average of 4.29 million, indicating normal recent market interest.

COMPASS Pathways plc (NASDAQ:CMPS) closed at $9.52 USD, gaining $0.51 (5.70%) from the previous close of $9.01. The stock is currently mid-range between its 52-week high and low $2.25 and $10.21. With a market capitalization of about $915.09 million, COMPASS Pathways plc is classified as a small-cap and shows higher-than-market volatility (beta ~2.02). Key stats such as the average daily volume over the past year has been around 5.08 million shares, in line with its 52-week average. Headquartered in London, None, COMPASS Pathways plc operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Kabir Kumar Nath, the company employs approximately 166 people and listed since September 18, 2020. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States.

COMPASS Pathways plc has 95.94 million shares outstanding. The public float is 58.41 million shares, elevated short interest at 8.26% of float. This equals 7.78 million shares. The short ratio is 4.18 days. Institutional investors hold 64.17% of the float. Insiders own 13.3%. ATAI Life Sciences N.V. holds 6.91 million shares, Malievskaia Ekaterina has 3.15 million shares and Goldsmith George Jay has 3.15 million shares.

COMPASS Pathways plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.38. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 9.72% annually over the next five years. The latest quarter delivered EPS of -$0.59. The next quarter is forecast at -$0.40. Next year's EPS is expected at -$2.31. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 10 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $70.00 to $6.00. The high target offers 672.63% upside. The low target suggests -33.77% downside. The mean target is $26.06. This offers 187.64% upside. COMPASS Pathways plc earnings surprise history is a mixed track record. The quarter that ended March 24, 2026, missed forecasts by 43.9%. The prior quarter beat by 261.13%. Over the last six quarters, Apple has recorded several small beats. These include -99.9% in October 31, 2024.

COMPASS Pathways plc trades at a P/E ratio of -2.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -15.96 indicating negative book value, which may reflect financial stress. The P/FCF stands at -5.51, also above market averages.

COMPASS Pathways plc (NASDAQ:CMPS) shares are flat 5.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows COMPASS Pathways plc trading at a premium to the broader market with a P/E of -2.93. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $45.79, suggesting 405.41% upside. Our AI forecast model points to short-term strength (3.42% over two weeks), a medium-term rise (33.11% over three months), and a longer-term gain (272.41% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that COMPASS Pathways plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.42%, with price expected at $9.37 by May 14, 2026, within a range of $8.02 to $10.80 3-Month Outlook: Projected rise of 33.11%, reaching $12.06 by July 29, 2026, with a range of $11.84 to $12.30. 1-Year Outlook: Projected gain of 272.41%, with price at $33.74 by April 30, 2027, within a range of $32.85 to $41.42.